Loading company…
US developer of boron neutron capture therapy, a targeted radiation treatment for cancer.
TAE Life Sciences develops boron neutron capture therapy (BNCT), a targeted radiation treatment for recurrent, invasive, untreatable and metastatic cancers that aims to spare healthy tissue. Founded in 2017 in the US, the company raised USD 30 mn in Series B funding from ARTIS Ventures and other investors on June 2, 2020. Bruce Bauer and Robert Hill are its co-CEOs. Its products are still in development and not commercially available.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in